Treatment Duration for Bullous Impetigo with Septra
Treat bullous impetigo with Septra (trimethoprim-sulfamethoxazole) for 7 days 1.
Guideline-Based Recommendation
The IDSA 2014 guidelines explicitly state that oral therapy for impetigo (both bullous and nonbullous) should be a 7-day regimen with an agent active against S. aureus 1. When MRSA is suspected or confirmed, sulfamethoxazole-trimethoprim (Septra) is specifically recommended 1.
Key Clinical Considerations
When to use Septra for bullous impetigo:
- MRSA is suspected or confirmed as the causative organism
- Patient has numerous lesions requiring systemic therapy
- Outbreak situations where transmission control is important
- Patient cannot tolerate first-line agents like dicloxacillin or cephalexin
Important caveats:
- The standard 7-day duration applies regardless of whether the impetigo is bullous or nonbullous 1
- If cultures yield streptococci alone, oral penicillin becomes the preferred agent rather than Septra 1
- Topical therapy (mupirocin or retapamulin for 5 days) may be sufficient for limited disease, but oral therapy is recommended for multiple lesions 1
Supporting Evidence
Research data supports the effectiveness of trimethoprim-sulfamethoxazole for impetigo treatment. A study in indigenous Australian children demonstrated that SXT (co-trimoxazole) achieved treatment success rates of approximately 78-86% for impetigo, with particular benefit noted in cases with scabies coinfection 2. This study used shorter durations (3-5 days), but the guideline recommendation of 7 days remains the standard for comprehensive treatment 1.
Clinical pitfall to avoid: Do not confuse the 5-day duration recommended for topical therapy (mupirocin/retapamulin) with oral antibiotic therapy—oral agents require 7 days 1.